ASCO Guideline on Stage IV NSCLC Therapy Updated

August 16, 2017 – An update of the ASCO clinical practice guideline on the systemic treatment of patients with stage IV non–small cell lung cancer (NSCLC) clarifies the role of immunotherapy in this setting. The update, published by Hanna et al in the Journal of Clinical Oncology, also provides new recommendations on the use of targeted therapies for patients with changes in tumor EGFR, ALK, and ROS1 genes. “Treatment for lung cancer has become increasingly … (leggi tutto)